Literature DB >> 34295704

Outcomes of contemporary imaging-guided management of sinus of Valsalva aneurysms.

Bo Xu1, Duygu Kocyigit1, Carlos Godoy-Rivas2, Jorge Betancor3, L Leonardo Rodriguez1, Venu Menon4, Wael Jaber1, Richard Grimm1, Scott D Flamm5, Paul Schoenhagen5, Lars G Svensson6, Brian P Griffin1.   

Abstract

BACKGROUND: Sinus of Valsalva aneurysms (SVAs) are rare. We assessed the role of multimodality imaging in guiding the contemporary management.
METHODS: A single-center retrospective cohort study over a 20-year period was performed.
RESULTS: Between January 1997 and June 2017, 103 patients were diagnosed with SVAs (median age: 58 years). Eighty patients presented with non-ruptured SVAs, and 23 with ruptured SVAs. Seventy-six patients underwent surgery, and 27 were conservatively managed. The median durations of follow-up were: 48 months (surgical group) vs. 37.5 months (conservative group). There was no mortality directly attributable to SVA surgery. There were no late complications in the conservative group. Transthoracic echocardiography (TTE) was the first-line imaging investigation (100.0% in surgical group vs. 92.6% in conservative group, P=0.019). Additional imaging studies included: (I) transesophageal echocardiography (TEE): 93.4% in surgical group vs. 22.2% in conservative group, P<0.001; (II) multi-detector cardiac computed tomography (MDCT): 61.8% in surgical group vs. 37.0% in conservative group, P=0.041; (III) cardiac magnetic resonance (CMR): 22.4% in surgical group vs. 14.8% in conservative group, P=0.579. At diagnosis, SVA diameters were: TTE: 4.80 cm (range, 3.30 cm); TEE: 5.40 cm (range, 4.00 cm); MDCT: 5.20 cm (range, 3.90 cm); CMR: 4.80 cm (range, 3.70 cm).
CONCLUSIONS: In a 20-year cohort, proper selection for surgery and conservative management resulted in excellent outcomes for SVAs. TTE was the first-line imaging investigation for assessment of SVAs, although many patients underwent an additional imaging investigation. The contemporary outcomes of imaging-guided SVA management were excellent. 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Sinus of Valsalva aneurysm (SVA); cardiac magnetic resonance imaging; cardiac surgery; multidetector cardiac computed tomography; multimodality imaging; transthoracic echocardiography

Year:  2021        PMID: 34295704      PMCID: PMC8261744          DOI: 10.21037/cdt-20-630

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  13 in total

1.  Surgical repair of a ruptured congenital sinus of Valsalva aneurysm: 10-year experience with 286 cases.

Authors:  Xiaokang Luo; Dong Zhang; Bo Li; Lei Qi; Li Gong; Yue Tang; Hansong Sun
Journal:  Eur J Cardiothorac Surg       Date:  2019-06-01       Impact factor: 4.191

2.  Aortic Measurements in Patients with Aortopathy are Larger and More Reproducible by Cardiac Magnetic Resonance Compared with Echocardiography.

Authors:  Atosa Nejatian; Johan Yu; Tal Geva; Matthew T White; Ashwin Prakash
Journal:  Pediatr Cardiol       Date:  2015-07-15       Impact factor: 1.655

3.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Roberto M Lang; Luigi P Badano; Victor Mor-Avi; Jonathan Afilalo; Anderson Armstrong; Laura Ernande; Frank A Flachskampf; Elyse Foster; Steven A Goldstein; Tatiana Kuznetsova; Patrizio Lancellotti; Denisa Muraru; Michael H Picard; Ernst R Rietzschel; Lawrence Rudski; Kirk T Spencer; Wendy Tsang; Jens-Uwe Voigt
Journal:  J Am Soc Echocardiogr       Date:  2015-01       Impact factor: 5.251

4.  Surgery for ruptured sinus of Valsalva aneurysm: 25-year experience with 55 patients.

Authors:  Sabit Sarikaya; Taylan Adademir; Ahmet Elibol; Fuat Büyükbayrak; Alper Onk; Kaan Kirali
Journal:  Eur J Cardiothorac Surg       Date:  2012-08-03       Impact factor: 4.191

Review 5.  Aortic valve and ascending aorta guidelines for management and quality measures.

Authors:  Lars G Svensson; David H Adams; Robert O Bonow; Nicholas T Kouchoukos; D Craig Miller; Patrick T O'Gara; David M Shahian; Hartzell V Schaff; Cary W Akins; Joseph E Bavaria; Eugene H Blackstone; Tirone E David; Nimesh D Desai; Todd M Dewey; Richard S D'Agostino; Thomas G Gleason; Katherine B Harrington; Susheel Kodali; Samir Kapadia; Martin B Leon; Brian Lima; Bruce W Lytle; Michael J Mack; Michael Reardon; T Brett Reece; G Russell Reiss; Eric E Roselli; Craig R Smith; Vinod H Thourani; E Murat Tuzcu; John Webb; Mathew R Williams
Journal:  Ann Thorac Surg       Date:  2013-06       Impact factor: 4.330

6.  Comparison of feasibility and accuracy of transthoracic echocardiography versus computed tomography in patients with known ascending aortic aneurysm.

Authors:  Gloria Tamborini; Claudia Agnese Galli; Anna Maltagliati; Daniele Andreini; Gianluca Pontone; Carlo Quaglia; Giovanni Ballerini; Mauro Pepi
Journal:  Am J Cardiol       Date:  2006-08-22       Impact factor: 2.778

7.  Effects of statin therapy on ascending aorta aneurysms growth: A propensity-matched analysis.

Authors:  Emiliano Angeloni; Angelo Vitaterna; Michele Pirelli; Simone Refice
Journal:  Int J Cardiol       Date:  2015-05-05       Impact factor: 4.164

8.  Surgical repair of sinus of Valsalva aneurysm in Asian patients.

Authors:  Zheng-jun Wang; Cheng-wei Zou; De-cai Li; Hong-xin Li; An-biao Wang; Gui-dao Yuan; Quan-xin Fan
Journal:  Ann Thorac Surg       Date:  2007-07       Impact factor: 4.330

Review 9.  Sinus of Valsalva Aneurysms: A State-of-the-Art Imaging Review.

Authors:  Bo Xu; Duygu Kocyigit; Jorge Betancor; Carmela Tan; E Rene Rodriguez; Paul Schoenhagen; Scott D Flamm; L Leonardo Rodriguez; Lars G Svensson; Brian P Griffin
Journal:  J Am Soc Echocardiogr       Date:  2020-03       Impact factor: 5.251

10.  Ruptured aneurysms of the sinus of Valsalva.

Authors:  E D Mayer; K Ruffmann; W Saggau; B Butzmann; K Bernhardt-Mayer; N Schatton; W Schmitz
Journal:  Ann Thorac Surg       Date:  1986-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.